Stock GANX GAIN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
3.03 USD -1.30% Intraday chart for Gain Therapeutics, Inc. -4.72% -7.20%
04-24 Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 CI
04-08 Gain Therapeutics Names Gene Mack as CFO MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gain Therapeutics Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease
AQ
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
GL
Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287
CI
Gain Therapeutics Names Gene Mack as CFO
MT
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
GL
Gain Therapeutics, Inc. Appoints Gene Mack as Chief Financial Officer
CI
Gain Therapeutics Names Chief Medical Officer
MT
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
GL
Gain Therapeutics, Inc. Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
CI
Gain Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
GL
Gain Therapeutics to Present at Public Ventures Discovery Day
GL
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
GL
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
GL
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
AQ
Gain Therapeutics, Inc. Appoints Gianluca Fuggetta as the Vice President of Finance and Principal Financial Officer from Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, Effective March 1, 2024
CI
Gain Therapeutics, Inc. Announces the Resignation of C. Evan Ballantyne as Chief Financial Officer, Effective March 1, 2024
CI
Certain Common Stock of Gain Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2024.
CI
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GANX Stock
  4. News Gain Therapeutics, Inc.